Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance

BMC Nephrology

Ondrej Viklicky⁴  Birgit Sawitzki²  Ilja Striz⁵  Petra Hruba¹  Peter Wohlfahrt³  Alena Sekerkova⁵  Irena Tycova¹  Eva Krepsova¹ 

[1] Transplant Laboratory, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;Institute of Medical Immunology and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), Charité University Medicine, Berlin, Germany;Department of Preventive Cardiology, Cardiology Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;Biomedical Centre, Faculty of Medicine in Plzen, Charles University in Prague, Plzen, Czech Republic;Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

关键词: Tolerance;    Rejection;    rATG;    Kidney transplantation;    FOXP3;    Basiliximab;   

Others  :  1223105
DOI  :  10.1186/s12882-015-0141-2

 received in 2015-06-17, accepted in 2015-08-06,  发布年份 2015

【 摘 要 】

Background

Induction therapy can improve kidney transplantation (KTx) outcomes, but little is known about the mechanisms underlying its effects.

Methods

The mRNA levels of T cell-related genes associated with tolerance or rejection (CD247, GZMB, PRF1, FOXP3, MAN1A1, TCAIM, and TLR5) and lymphocyte subpopulations were monitored prospectively in the peripheral blood of 60 kidney transplant recipients before and 7, 14, 21, 28, 60, 90 days, 6 months, and 12 months after KTx. Patients were treated with calcineurin inhibitor-based triple immunosuppression and induction with rabbit anti-thymocyte globulin (rATG, n = 24), basiliximab (n = 17), or without induction (no-induction, n = 19). A generalized linear mixed model with gamma distribution for repeated measures, adjusted for rejection, recipient/donor age and delayed graft function, was used for statistical analysis.

Results

rATG treatment caused an intense reduction in all T cell type population and natural killer (NK) cells within 7 days, then a slow increase and repopulation was observed. This was also noticed in the expression levels of CD247, FOXP3, GZMB, and PRF1. The basiliximab group exhibited higher CD247, GZMB, FOXP3 and TCAIM mRNA levels and regulatory T cell (Treg) counts than the no-induction group. The levels of MAN1A1 and TLR5 mRNA expressions were increased, whereas TCAIM decreased in the rATG group as compared with those in the no-induction group.

Conclusion

The rATG induction therapy was associated with decreased T and NK cell-related transcript levels and with upregulation of two rejection-associated transcripts (MAN1A1 and TLR5) shortly after KTx. Basiliximab treatment was associated with increased absolute number of Treg cells, and increased level of FOXP3 and TCAIM expression.

【 授权许可】

   
2015 Krepsova et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011; 378:1419-1427.
• [2]Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B et al.. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med. 2001; 344:947-954.
• [3]Simon T, Opelz G, Wiesel M, Ott RC, Susal C. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant. 2003; 3:1121-1127.
• [4]Alvarez CM, Paris SC, Arango L, Arbelaez M, Garcia LF. Kidney transplant patients with long-term graft survival have altered expression of molecules associated with T-cell activation. Transplantation. 2004; 78:1541-1547.
• [5]Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P et al.. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest. 2010; 120:1848-1861.
• [6]Sawitzki B, Bushell A, Steger U, Jones N, Risch K, Siepert A et al.. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant. 2007; 7:1091-1102.
• [7]Louis S, Braudeau C, Giral M, Dupont A, Moizant F, Robillard N et al.. Contrasting CD25hiCD4 + T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation. 2006; 81:398-407.
• [8]Iwase H, Kobayashi T, Kodera Y, Miwa Y, Kuzuya T, Iwasaki K, Haneda M et al.. Clinical significance of regulatory T-cell-related gene expression in peripheral blood after renal transplantation. Transplantation. 2011; 91:191-198.
• [9]Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation. 2012; 93:1-10.
• [10]Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol. 2004; 4:675-687.
• [11]Bluestone JA. Mechanisms of tolerance. Immunol Rev. 2011; 241:5-19.
• [12]Herscovics A. Structure and function of Class I alpha 1,2-mannosidases involved in glycoprotein synthesis and endoplasmic reticulum quality control. Biochimie. 2001; 83:757-762.
• [13]KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9 Suppl 3:S1-155.
• [14]Krystufkova E, Sekerkova A, Striz I, Brabcova I, Girmanova E, Viklicky O. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. Nephrol Dial Transplant. 2012; 27:2576-2582.
• [15]Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS et al.. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant. 2010; 10:2132-2141.
• [16]Vondran FW, Timrott K, Tross J, Kollrich S, Schwarz A, Lehner F et al.. Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation. Transpl Int. 2010; 23:514-523.
• [17]Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE et al.. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007; 7:518-526.
• [18]Wang Z, Shi BY, Qian YY, Cai M, Wang Q. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. Clin Exp Immunol. 2009; 155:496-503.
• [19]Abadja F, Alamartine E, Berthoux F, Mariat C, Genin C, Lambert C. Quantification of circulating regulatory T cells by flow cytometry in kidney transplant patients after basiliximab induction therapy. Transplantation. 2010; 89:366-368.
• [20]Kho MM, Bouvy AP, Cadogan M, Kraaijeveld R, Baan CC, Weimar W. The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol. 2012; 26:186-190.
• [21]Sageshima J, Ciancio G, Guerra G, Gaynor JJ, Cova D, Zarak A et al.. Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation. Transpl Immunol. 2011; 25:104-111.
• [22]Vacher-Coponat H, Brunet C, Moal V, Loundou A, Bonnet E, Lyonnet L et al.. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine. Transplantation. 2006; 82:558-566.
• [23]Hadaya K, Avila Y, Valloton L, de Rham C, Bandelier C, Ferrari-Lacraz S et al.. Natural killer cell receptor--repertoire and functions after induction therapy by polyclonal rabbit anti-thymocyte globulin in unsensitized kidney transplant recipients. Clin Immunol. 2010; 137:250-260.
• [24]Sewgobind VD, Kho MM, van der Laan LJ, Hendrikx TK, van Dam T, Tilanus HW et al.. The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant. 2009; 24:1635-1644.
• [25]Simon T, Opelz G, Weimer R, Wiesel M, Feustel A, Ott RC et al.. The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period. Clin Transplant. 2003; 17:217-224.
• [26]Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc. 2004; 36:25S-32S.
• [27]Janas ML, Groves P, Kienzle N, Kelso A. IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. J Immunol. 2005; 175:8003-8010.
• [28]Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol. 2007; 178:280-290.
• [29]Murawski MR, Litherland SA, Clare-Salzler MJ, Davoodi-Semiromi A. Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann N Y Acad Sci. 2006; 1079:198-204.
• [30]Cheriyan VT, Thomas C, Balaram P. Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy. J Cancer Res Clin Oncol. 2011; 137:1435-1444.
• [31]Vogel SZ, Schlickeiser S, Jurchott K, Akyuez L, Schumann J, Appelt C et al.. TCAIM decreases T cell priming capacity of dendritic cells by inhibiting TLR-induced Ca2+ influx and IL-2 production. J Immunol. 2015; 194:3136-3146.
• [32]Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004; 5:987-995.
• [33]Jenner J, Kerst G, Handgretinger R, Muller I. Increased alpha2,6-sialylation of surface proteins on tolerogenic, immature dendritic cells and regulatory T cells. Exp Hematol. 2006; 34:1212-1218.
• [34]Sawitzki B, Brunstein C, Meisel C, Schumann J, Vogt K, Appelt C et al.. Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression. Biol Blood Marrow Transplant. 2014; 20:173-182.
• [35]Uematsu S, Fujimoto K, Jang MH, Yang BG, Jung YJ, Nishiyama M et al.. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol. 2008; 9:769-776.
• [36]Braudeau C, Ashton-Chess J, Giral M, Dugast E, Louis S, Pallier A et al.. Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation. 2008; 86:130-136.
• [37]Gebuhr I, Keeren K, Vogt K, Höflich C, Appelt C, Schlieer U et al.. Differential expression and function of alpha-mannosidase I in stimulated naive and memory CD4+ T cells. J Immunother. 2011; 34:428-437.
• [38]Keeren K, Friedrich M, Gebuhr I, Philipp S, Sabat R, Sterry W et al.. Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies. J Immunol. 2009; 183:4077-4087.
• [39]Hutchinson JA, Riquelme P, Sawitzki B, Tomiuk S, Miqueu P, Zuhayra M et al.. Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol. 2011; 187:2072-2078.
• [40]Siepert A, Ahrlich S, Vogt K, Appelt C, Stanko K, Kühl A et al.. Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells. Am J Transplant. 2012; 12:2384-2394.
• [41]Schumann J, Stanko K, Woertge S, Appelt C, Schumann M, Kühl AA et al.. The Mitochondrial Protein TCAIM Regulates Activation of T Cells and Thereby Promotes Tolerance Induction of Allogeneic Transplants. Am J Transplant. 2014; 14:2723-2735.
• [42]Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M et al.. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008; 8:2086-2096.
• [43]de Goer de Herve MG, Gonzales E, Hendel-Chavez H, Décline JL, Mourier O, Abbed K et al.. CD25 appears non essential for human peripheral T(reg) maintenance in vivo. PLoS One. 2010; 5: Article ID e11784
• [44]Bouvy AP, Klepper M, Kho MM, Boer K, Betjes MG, Weimar W et al.. The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients. Nephrol Dial Transplant. 2014; 29:1587-1597.